Certara (NASDAQ:CERT) PT Lowered to $16.00

Certara (NASDAQ:CERT) had its price objective cut by research analysts at UBS Group from $20.00 to $16.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price target suggests a potential upside of 24.03% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Barclays decreased their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. JMP Securities reiterated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Finally, KeyCorp reduced their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $18.83.

Certara Stock Down 1.3 %

Shares of NASDAQ:CERT traded down $0.17 during midday trading on Wednesday, reaching $12.90. 21,381 shares of the company were exchanged, compared to its average volume of 572,288. The firm has a market cap of $2.07 billion, a PE ratio of -33.51, a P/E/G ratio of 5.39 and a beta of 1.52. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.27. Certara has a fifty-two week low of $11.81 and a fifty-two week high of $19.87. The stock has a fifty day simple moving average of $15.02 and a two-hundred day simple moving average of $16.50.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The firm had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. During the same period in the prior year, the company earned $0.10 earnings per share. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. As a group, sell-side analysts forecast that Certara will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Pineridge Advisors LLC acquired a new stake in shares of Certara in the 4th quarter valued at about $28,000. Global Retirement Partners LLC grew its position in Certara by 5,306.3% in the 1st quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock valued at $31,000 after purchasing an additional 1,698 shares during the period. Blue Trust Inc. bought a new stake in Certara during the 2nd quarter valued at $26,000. Innealta Capital LLC acquired a new position in Certara during the second quarter worth $36,000. Finally, YHB Investment Advisors Inc. acquired a new position in shares of Certara during the first quarter valued at about $47,000. 73.96% of the stock is owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.